Inventiva S.A. (ETR:6IV)
Germany · Delayed Price · Currency is EUR | Market Cap | 661.58M -5.8% |
| Revenue (ttm) | 2.46M -85.5% |
| Net Income | -247.72M |
| EPS | -0.92 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,814 |
| Open | 2.875 |
| Previous Close | 3.000 |
| Day's Range | 2.815 - 2.945 |
| 52-Week Range | 2.735 - 6.150 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 28, 2026 |
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr... [Read more]
Financial Performance
In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.
Financial StatementsNews
Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
Daix (France), New York City (New York, United States), October 6, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), (“Inventiva” or the “Company”), a clinical-stage bi...
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-ass...
Inventiva price target raised to $18 from $13 at Truist
Truist raised the firm’s price target on Inventiva (IVA) to $18 from $13 and keeps a Buy rating on the shares. Following a deep dive into the company’s Phase 2b…
Inventiva Transcript: Stifel 2026 Virtual Cardiometabolic Forum
Lanifibranor's phase III NATiV3 trial in MASH is fully enrolled, with top-line data expected Q4 2026. Its balanced pan-PPAR mechanism offers differentiated efficacy and tolerability, targeting metabolic and fibrotic drivers. Plans include independent launch, strong financial runway, and potential expansion into advanced indications.
Inventiva (IVA): H1 Results Put Cash Runway and NATiV3 at the Center of the Story
Inventiva S.A. (NASDAQ: IVA) is still a clinical-stage biopharmaceutical company, so its latest reported numbers are less about current revenue... The post Inventiva (IVA): H1 Results Put Cash Runway ...
Inventiva (IVA) Q2 2026 Earnings Call Transcript
Lanifibranor Phase III results expected Q4 2026, potential FDA submission H1 2027.
Inventiva price target raised to $21 from $20 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Inventiva (IVA) to $21 from $20 and keeps a Buy rating on the shares. Inventiva reported 1H26 earnings ahead of…
Inventiva Q2 Earnings Call Highlights
Inventiva NASDAQ: IVA said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth qu...
Inventiva Earnings Call Transcript: Q2 2026
Lanifibranor advanced to phase III with top-line MASH data expected in Q4 2026, supported by a strengthened financial position and preparations for regulatory filings and commercial launch. Cash runway extends through key milestones, with significant market opportunity and robust clinical data underpinning outlook.
Inventiva Earnings release: Q2 2026
Inventiva released its Q2 2026 earnings on September 28, 2026, summarizing the period's financial results.
Inventiva Slides: Q2 2026
Inventiva has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 28, 2026.
Inventiva Quarterly report: Q2 2026
Inventiva has published its Q2 2026 quarterly earnings report on September 28, 2026.
Inventiva Reports Narrower H1 Loss; MASH Drug Readout Expected This Quarter
(RTTNews) - Inventiva (IVA), a clinical-stage biopharmaceutical company developing lanifibranor for metabolic dysfunction-associated steatohepatitis (MASH), reported its first-half 2026 financial resu...
Inventiva S.A. Reports Zero Revenues in H1 2026, Stock Ticker IVA
Inventiva S.A. Reports Zero Revenues in H1 2026, Stock Ticker IVA
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused o...
Inventiva SA at Morgan Stanley Global Healthcare Conference Transcript
Inventiva SA at Morgan Stanley Global Healthcare Conference Transcript
Inventiva Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Lanifibranor is nearing a pivotal phase III readout, aiming to address both liver and metabolic drivers of MASH with a dual mechanism. The drug is positioned for rapid efficacy, manageable safety, and compatibility with combination therapies, targeting a growing market and future expansion into advanced disease stages.
Inventiva price target raised to $14 from $11 at Guggenheim
Guggenheim analyst Seamus Fernandez raised the firm’s price target on Inventiva (IVA) to $14 from $11 and keeps a Buy rating on the shares ahead of the NATiV3 Phase 3…
RUBIS: H1 2026 Results - Strong performance leading way to upgrade of 2026 guidance
Paris, 08 September 2026, 7:00am EBITDA at €434m, +18% yoy reflecting sustained demand, disciplined execution and optimised inventory management in a volatile and high oil price context, highlighting ...
Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4
(RTTNews) - Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company, on Thursday announced the last patient visit in the Phase 3 NATiV3 trial for Lanifibranor in treating metabolic dysfunctio...
Inventiva announces last patient visit in NATiV3 trial
Inventiva (IVA) announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for the treatment of patients with MASH with moderate…
Inventiva Names Chris Benecchi As COO Ahead Of Lanifibranor's Phase 3 Readout
(RTTNews) - Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company, on Monday announced the appointment of Chris Benecchi as Chief Operating Officer (COO).
Inventiva appoints Chris Benecchi as COO
Inventiva (IVA) announced the appointment of Chris Benecchi as COO. Benecchi will lead Inventiva’s operational readiness as the company approaches its NATiV3 Phase 3 topline study results of lanifibra...
Inventiva Appoints Chris Benecchi as Chief Operating Officer
Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026...